COVERAGE & SUPPORT
Use ASCVD and HeFH ICD-10-CM codes to start your appropriate patients on NEXLIZET and NEXLETOL today.
Download ICD-10-CM Reference Guide
ASCVD=atherosclerotic cardiovascular disease; HeFH=heterozygous familial hypercholesterolemia.
Back to top
NEXLIZET and NEXLETOL have partnered with ASPN Pharmacy to help your practice with prior authorization needs, and to help your patients when filling their prescriptions.
Download Prior Authorization Checklist
Download ASPN Pharmacy Guide
Download Asembia Referral Form
Download NEXLIZET template
Download NEXLETOL template
Patients can request a new Co-Pay Card or activate an existing one:
*Certain restrictions apply. See Terms and Conditions.
Need more information?
For questions about the NEXLIZET & NEXLETOL Co-Pay Card,
call 1-855-699-8814 (8:00AM-8:00PM ET, Monday-Friday, excluding holidays).
STAY IN THE KNOW
Get updates about NEXLIZET and NEXLETOL
right to your inbox!
Learn more about the Phase 3 trial and the efficacy of adding NEXLIZET
Interested in samples of NEXLIZET or NEXLETOL?
NEXLETOL and NEXLIZET are indicated as adjuncts to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Limitations of Use: The effect of NEXLETOL and NEXLIZET on cardiovascular morbidity and mortality has not been determined.
IMPORTANT SAFETY INFORMATION
Contraindications: NEXLETOL has no contraindications. NEXLIZET is contraindicated in patients with a known hypersensitivity to ezetimibe tablets. Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported with ezetimibe.
Warnings and Precautions: Hyperuricemia: Bempedoic acid, a component of NEXLETOL and NEXLIZET, may increase blood uric acid levels. Hyperuricemia may occur early in treatment and persist throughout treatment, and may lead to the development of gout, especially in patients with a history of gout. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
Tendon Rupture: Bempedoic acid is associated with an increased risk of tendon rupture or injury. In clinical trials, tendon rupture occurred in 0.5% of patients treated with bempedoic acid versus 0% of patients treated with placebo, and involved the rotator cuff (the shoulder), biceps tendon, or Achilles tendon. Tendon rupture occurred within weeks to months of starting bempedoic acid. Tendon rupture may occur more frequently in patients over 60 years of age, patients taking corticosteroid or fluoroquinolone drugs, patients with renal failure, and patients with previous tendon disorders. Discontinue NEXLETOL or NEXLIZET at the first sign of tendon rupture. Avoid NEXLETOL and NEXLIZET in patients who have a history of tendon disorders or tendon rupture.
Adverse Reactions: In NEXLETOL clinical trials, the most commonly reported adverse reactions were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes. Reactions reported less frequently, but still more often than with placebo, included benign prostatic hyperplasia and atrial fibrillation.
In the NEXLIZET clinical trial, the most commonly reported adverse reactions observed with NEXLIZET, but not observed in clinical trials of bempedoic acid or ezetimibe, a component of NEXLIZET, and occurring more frequently than with placebo, were urinary tract infection, nasopharyngitis, and constipation.
Adverse reactions reported in clinical trials of ezetimibe, and occurring at an incidence greater than with placebo, included upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and influenza. Other adverse reactions reported in postmarketing use of ezetimibe included hypersensitivity reactions, including anaphylaxis, angioedema, rash, and urticaria; erythema multiforme; myalgia; elevated creatine phosphokinase; myopathy/rhabdomyolysis; elevations in liver transaminases; hepatitis; abdominal pain; thrombocytopenia; pancreatitis; nausea; dizziness; paresthesia; depression; headache; cholelithiasis; cholecystitis.
Drug Interactions: Simvastatin and Pravastatin: Concomitant use with bempedoic acid results in increased concentrations and increased risk of simvastatin or pravastatin-related myopathy. Use of either NEXLETOL or NEXLIZET with greater than 20 mg of simvastatin or 40 mg of pravastatin should be avoided.
Cyclosporine: Caution should be exercised when using NEXLIZET and cyclosporine concomitantly due to increased exposure to both ezetimibe and cyclosporine. Monitor cyclosporine concentrations in patients receiving NEXLIZET and cyclosporine. In patients treated with cyclosporine, the potential effects of the increased exposure to ezetimibe from concomitant use should be carefully weighed against the benefits of alterations in lipid levels provided by NEXLIZET.
Fibrates: Coadministration of NEXLIZET with fibrates other than fenofibrate is not recommended. Fenofibrate and ezetimibe may increase cholesterol excretion into the bile, leading to cholelithiasis. If cholelithiasis is suspected in a patient receiving NEXLIZET and fenofibrate, gallbladder studies are indicated and alternative lipid-lowering therapy should be considered.
Cholestyramine: Concomitant use of NEXLIZET and cholestyramine decreases ezetimibe concentration. This may result in a reduction of efficacy. Administer NEXLIZET either at least 2 hours before, or at least 4 hours after, bile acid sequestrants.
Lactation and Pregnancy: It is not recommended that NEXLETOL or NEXLIZET be taken during breastfeeding. Discontinue NEXLETOL or NEXLIZET when pregnancy is recognized, unless the benefits of therapy outweigh the potential risks to the fetus. Based on the mechanism of action of bempedoic acid, NEXLETOL and NEXLIZET may cause fetal harm.
Please see full Prescribing Information for NEXLIZET and NEXLETOL.
Medical Information Contact Center: 1-833-377-7633 (toll free, US only), Monday-Friday, 8:00am-8:00pm ET
All trademarks and trade names are the property of their respective
© 2021 ESPERION Therapeutics, Inc. All
rights reserved. 09/21 US-NXTL-2100266
The link you have selected will take you away from NEXLIZETHCP.com to an external website.
ESPERION Therapeutics, Inc. does not endorse and is not responsible for the content included on, or the way in which information is processed by, external websites. Linking to third-party sites is at your own risk. Your use of third-party websites is subject to the terms and conditions and the privacy policies of those individual sites.
A patient may be eligible for the NEXLETOL & NEXLIZET Co-Pay Card if they meet the
eligibility criteria below:
Should a patient have any change in insurance coverage or become enrolled in a Government Program during their enrollment in the NEXLETOL & NEXLIZET Co-Pay Card program, they must inform a NEXLETOL & NEXLIZET Co-Pay Card program representative and will no longer be eligible for the NEXLETOL & NEXLIZET Co-Pay Card program. Also, if a patient is enrolled in a Government Program, they may not use the NEXLETOL & NEXLIZET Co-Pay Card program even if they elect to be processed as a commercial or discount insurance plan patient.
To determine if a patient is eligible for the NEXLETOL & NEXLIZET Co-Pay Card program, the patient must enroll online at www.NexCopay.com, or call 855-699-8814, and opt-in to the NEXLETOL & NEXLIZET Co-Pay Card program. ESPERION will evaluate the patient’s eligibility and communicate an eligibility decision to the patient. Final patient eligibility determinations are provided by ESPERION and/or its program representatives.
Eligibility in the NEXLETOL & NEXLIZET Co-Pay Card program is for one year. Patients must reenroll for NEXLETOL & NEXLIZET Co-Pay assistance each year that they wish to participate in the program. If your card is lost or stolen, please visit www.NexCopay.com, or call 855-699-8814.
Eligible patients with commercial prescription drug insurance coverage for NEXLETOL or NEXLIZET may pay as little as $10 per fill for up to a 3-month supply. The NEXLETOL & NEXLIZET Co-Pay Card is not health insurance or a benefit plan. Distribution or use of the NEXLETOL & NEXLIZET Co-Pay Card does not obligate use or continuing use of any provider or continuing use of NEXLETOL or NEXLIZET. Patient is responsible for reporting the receipt of all NEXLETOL & NEXLIZET Co-Pay Card savings or reimbursement to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Co-Pay Card, as may be required.
The NEXLETOL & NEXLIZET Co-Pay Card is not valid for medications the patient receives for free or that are eligible to be reimbursed by other healthcare or pharmaceutical assistance programs that reimburse the patient in part or for the entire cost of his/her ESPERION medication. By using the NEXLETOL & NEXLIZET Co-Pay Card, the patient agrees not to seek reimbursement from health insurance or any third party for all or any part of the benefit received by the patient through the offer.
The NEXLETOL & NEXLIZET Co-Pay Card will be accepted by participating pharmacies in the United States. To qualify for use of this NEXLETOL & NEXLIZET Co-Pay Card, the patient may be required to pay out-of-pocket expenses for each prescription. The NEXLETOL & NEXLIZET Co-Pay Card program does not cover costs associated with a patient visit to a doctor’s office including prescriber, staff, administrative charges, labs, and other ancillary services. This NEXLETOL & NEXLIZET Co-Pay Card is only available with a valid prescription and cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription. This offer is not conditioned on any past, present or future purchase, including refills.
Use of this NEXLETOL & NEXLIZET Co-Pay Card must be consistent with all relevant health insurance requirements and payer agreements. The NEXLETOL & NEXLIZET Co-Pay Card may not be sold, purchased, traded, or offered for sale, purchase, or trade. The NEXLETOL & NEXLIZET Co-Pay Card is limited to one per person during this offer period and is non-transferable. Void where prohibited or otherwise restricted by law.
ESPERION reserves the right to rescind, revoke, amend, or terminate the program without notice at any time.
If you have questions or need additional support, call 855-699-8814 (8:00 am-8:00 pm ET, Monday-Friday, excluding holidays).
BY USING THIS PROGRAM, YOU UNDERSTAND AND AGREE TO COMPLY WITH
THESE TERMS AND CONDITIONS. ANY VIOLATIONS OR NON-COMPLIANCE
WITH THESE TERMS AND CONDITIONS MAY RESULT IN YOUR ELIGIBILITY
DETERMINATION FOR THE PROGRAM BEING RESCINDED.